Quick Search
Products Bivalirudin, Human
| Catalogue number: | B2102-50 |
| Size: | 1mg |
| Form: | Supplied as a lyophilized powder in manntiol, sodium hydroxide, pH 5.5. Reconstitute with sterile ddH2O, 0.1% BSA or HSA to a concentration of >100ug/ml, which can then be further diluted to other aqueous solutions. |
| Purity: | (same/more than) 95% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. Endotoxin: < 0.1ng/ug (IEU/ug) of Bivalirudin. |
| References: | 1. Effect of bivalirudin on length of stay in the recovery area after percutaneous coronary intervention compared with heparin alone, heparin + abciximab, or heparin + eptifibatide. Schussler JM, Cameron CS, Donsky MS, Am J Cardiol 2004 Dec 1;94(11):1417-9 2. Cardiopulmonary bypass with bivalirudin in type II heparin-induced thrombocytopenia. Clayton SB, Acsell JR, Uber WE, Ann Thorac Surg 2004 Dec;78(6):2167-9 3. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Cohen DJ, Lincoff AM, Chen HL, Sarembock IJ, J Am Coll Cardiol 2004 Nov 2;44(9):1792-800 4. Bivalirudin versus heparin as an antithrombotic agent in patients treated with a sirolimus-eluting stent. Rha SW, Kuchulakanti PK, Cheneau E, Aggrey G, Am J Cardiol 2004 Oct 15;94(8):1047-50 5. Addition of heparin to contrast media is associated with increased bleeding and peripheral vascular complications during percutaneous coronary intervention with bivalirudin and drug-eluting stents. Rha SW, Kuchulakanti PK, Cheneau E, Pichard AD, Cardiovasc Radiat Med 2004 Apr-Jun;5(2):64-70 6. Visual compatibility of bivalirudin with selected drugs. Hartman CA, Faria CE, Am J Health Syst Pharm 2004 Sep 1;61(17):1774, 1776. |
Get the Best Promotions
